CNS Pharmaceuticals Ownership 2024 | Who Owns CNS Pharmaceuticals Now?


OverviewRevenueFinancialsChart

Institutional Ownership

96.10%

Insider Ownership

8.55%

Retail Ownership

-4.66%

Institutional Holders

16.00

CNS Pharmaceuticals Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ARMISTICE CAPITAL, LLC9.11%0.00%124,000-9,229-6.93%124,000,000Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC1.97%-26,80026,800100.00%27,000Mar 31, 2023
CITADEL ADVISORS LLC0.97%-13,19613,196100.00%13,196,000Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)0.86%0.00%11,7027,325167.35%12,000Mar 31, 2023
VIRTU FINANCIAL LLC0.82%0.00%11,11911,119100.00%11,000Mar 31, 2023
UBS GROUP AG0.18%-2,4571,244102.56%2,457,000Mar 31, 2023
WELLS FARGO & COMPANY/MN0.04%-482--482,000Mar 31, 2023
FMR LLC0.01%-200200100.00%200,000Mar 31, 2023
GLOBAL RETIREMENT PARTNERS, LLC0.00%-531955.88%102,000Mar 31, 2023
BANK OF AMERICA CORP /DE/0.00%-25--25,000Mar 31, 2023
GRADIENT INVESTMENTS LLC0.00%-7--7,000Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.0.00%-11100.00%1,000Mar 31, 2023
PLANTE MORAN FINANCIAL ADVISORS, LLC0.00%-1--1,000Mar 31, 2023
PNC FINANCIAL SERVICES GROUP, INC.----8-100.00%-Mar 31, 2023

CNS Pharmaceuticals's largest institutional shareholder is ARMISTICE CAPITAL, LLC, holding 9.11% of the company's total share outstanding, currently valued at $124.00M. The top 10 institutional shareholders own together 13.96% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ARMISTICE CAPITAL, LLC9.11%0.00%124,000-9,229-6.93%124,000,000Mar 31, 2023
VIRTU FINANCIAL LLC0.82%0.00%11,11911,119100.00%11,000Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)0.86%0.00%11,7027,325167.35%12,000Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC1.97%-26,80026,800100.00%27,000Mar 31, 2023
GLOBAL RETIREMENT PARTNERS, LLC0.00%-531955.88%102,000Mar 31, 2023
CITADEL ADVISORS LLC0.97%-13,19613,196100.00%13,196,000Mar 31, 2023
UBS GROUP AG0.18%-2,4571,244102.56%2,457,000Mar 31, 2023
GRADIENT INVESTMENTS LLC0.00%-7--7,000Mar 31, 2023
WELLS FARGO & COMPANY/MN0.04%-482--482,000Mar 31, 2023
PLANTE MORAN FINANCIAL ADVISORS, LLC0.00%-1--1,000Mar 31, 2023
FMR LLC0.01%-200200100.00%200,000Mar 31, 2023
BANK OF AMERICA CORP /DE/0.00%-25--25,000Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.0.00%-11100.00%1,000Mar 31, 2023
PNC FINANCIAL SERVICES GROUP, INC.----8-100.00%-Mar 31, 2023

The largest CNS Pharmaceuticals shareholder by % of total assets is ARMISTICE CAPITAL, LLC. The company owns 124.00K shares of CNS Pharmaceuticals (CNSP), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RENAISSANCE TECHNOLOGIES LLC1.97%-26,80026,800100.00%27,000Mar 31, 2023
CITADEL ADVISORS LLC0.97%-13,19613,196100.00%13,196,000Mar 31, 2023
VIRTU FINANCIAL LLC0.82%0.00%11,11911,119100.00%11,000Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)0.86%0.00%11,7027,325167.35%12,000Mar 31, 2023
UBS GROUP AG0.18%-2,4571,244102.56%2,457,000Mar 31, 2023
FMR LLC0.01%-200200100.00%200,000Mar 31, 2023
GLOBAL RETIREMENT PARTNERS, LLC0.00%-531955.88%102,000Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.0.00%-11100.00%1,000Mar 31, 2023
BANK OF AMERICA CORP /DE/0.00%-25--25,000Mar 31, 2023
PLANTE MORAN FINANCIAL ADVISORS, LLC0.00%-1--1,000Mar 31, 2023
WELLS FARGO & COMPANY/MN0.04%-482--482,000Mar 31, 2023
GRADIENT INVESTMENTS LLC0.00%-7--7,000Mar 31, 2023
PNC FINANCIAL SERVICES GROUP, INC.----8-100.00%-Mar 31, 2023
ARMISTICE CAPITAL, LLC9.11%0.00%124,000-9,229-6.93%124,000,000Mar 31, 2023

As of Mar 31 2023, CNS Pharmaceuticals's largest institutional buyer is RENAISSANCE TECHNOLOGIES LLC. The company purchased 26.80K stocks of CNSP, valued at $27.00K.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ARMISTICE CAPITAL, LLC9.11%0.00%124,000-9,229-6.93%124,000,000Mar 31, 2023
PNC FINANCIAL SERVICES GROUP, INC.----8-100.00%-Mar 31, 2023
GRADIENT INVESTMENTS LLC0.00%-7--7,000Mar 31, 2023
WELLS FARGO & COMPANY/MN0.04%-482--482,000Mar 31, 2023
PLANTE MORAN FINANCIAL ADVISORS, LLC0.00%-1--1,000Mar 31, 2023
BANK OF AMERICA CORP /DE/0.00%-25--25,000Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.0.00%-11100.00%1,000Mar 31, 2023
GLOBAL RETIREMENT PARTNERS, LLC0.00%-531955.88%102,000Mar 31, 2023
FMR LLC0.01%-200200100.00%200,000Mar 31, 2023
UBS GROUP AG0.18%-2,4571,244102.56%2,457,000Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)0.86%0.00%11,7027,325167.35%12,000Mar 31, 2023
VIRTU FINANCIAL LLC0.82%0.00%11,11911,119100.00%11,000Mar 31, 2023
CITADEL ADVISORS LLC0.97%-13,19613,196100.00%13,196,000Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC1.97%-26,80026,800100.00%27,000Mar 31, 2023

As of Mar 31 2023, CNS Pharmaceuticals's biggest institutional seller is ARMISTICE CAPITAL, LLC. The company sold -9.23K shares of CNSP, valued at $124.00M.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RENAISSANCE TECHNOLOGIES LLC1.97%-26,80026,800100.00%27,000Mar 31, 2023
CITADEL ADVISORS LLC0.97%-13,19613,196100.00%13,196,000Mar 31, 2023
VIRTU FINANCIAL LLC0.82%0.00%11,11911,119100.00%11,000Mar 31, 2023
FMR LLC0.01%-200200100.00%200,000Mar 31, 2023
ADVISOR GROUP HOLDINGS, INC.0.00%-11100.00%1,000Mar 31, 2023

CNS Pharmaceuticals's largest new institutional shareholder by number of shares is RENAISSANCE TECHNOLOGIES LLC, purchased 26.80K shares, valued at $27.00K, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
PNC FINANCIAL SERVICES GROUP, INC.----8-100.00%-Mar 31, 2023

CNS Pharmaceuticals's largest sold out institutional shareholder by shares sold is PNC FINANCIAL SERVICES GROUP, INC., sold -8.00 shares, valued at -, as of undefined.

CNS Pharmaceuticals Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
VANGUARD INDEX FUNDS0.00%453,615--Dec 31, 2023
FIDELITY CONCORD STREET TRUST0.00%128,393--Feb 29, 2024
VANGUARD INDEX FUNDS0.00%116,73892,973391.22%Dec 31, 2023
EQ ADVISORS TRUST0.00%2,886--Dec 31, 2023
iSHARES TRUST0.00%38,201--Feb 29, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%3,118--Dec 31, 2023

CNS Pharmaceuticals's largest mutual fund holder by % of total assets is "VANGUARD INDEX FUNDS", owning 453.62K shares, compromising 0.00% of its total assets.

CNS Pharmaceuticals Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
30 Sep, 2216-5.88%
30 Jun, 22176.25%
31 Mar, 2216-11.11%
31 Dec, 21185.88%
30 Sep, 2117-5.56%
30 Jun, 21185.88%
31 Mar, 211770.00%
31 Dec, 201042.86%
30 Sep, 20716.67%
30 Jun, 206-33.33%
31 Mar, 20950.00%
31 Dec, 196-

As of 30 Sep 22, 16 institutions are holding CNS Pharmaceuticals's shares, representing a decrease of -5.88% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
30 Sep, 221,282,3897.15%
30 Jun, 221,196,819-30.11%
31 Mar, 221,712,43049.80%
31 Dec, 211,143,17920.64%
30 Sep, 21947,605-28.57%
30 Jun, 211,326,6644.15%
31 Mar, 211,273,79083.12%
31 Dec, 20695,601567.42%
30 Sep, 20104,22311.52%
30 Jun, 2093,458-9.61%
31 Mar, 20103,39415.11%
31 Dec, 1989,825-

CNS Pharmaceuticals (CNSP) has 1.28M shares outstanding as of 30 Sep 22, up 7.15% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
30 Sep, 2296.10%1.19%
30 Jun, 2289.69%0.51%
31 Mar, 22132.38%0.78%
31 Dec, 21130.14%1.21%
30 Sep, 21103.59%0.42%
30 Jun, 21156.49%0.65%
31 Mar, 21154.93%0.98%
31 Dec, 20125.57%34.90%
30 Sep, 2018.97%6.53%
30 Jun, 2017.04%4.79%
31 Mar, 2018.86%5.90%
31 Dec, 1917.88%-

As of 30 Sep 22, CNS Pharmaceuticals is held by 96.10% institutional shareholders, representing a 1.19% growth compared to 30 Jun 22.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
30 Sep, 227-22.22%
30 Jun, 229-10.00%
31 Mar, 221025.00%
31 Dec, 218-11.11%
30 Sep, 219-
30 Jun, 219-30.77%
31 Mar, 2113225.00%
31 Dec, 20433.33%
30 Sep, 203200.00%
30 Jun, 201-83.33%
31 Mar, 206-
31 Dec, 196-

7 institutional shareholders have increased their position in CNSP stock as of 30 Sep 22 compared to 9 in the previous quarter (a -22.22% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
30 Sep, 221-50.00%
30 Jun, 222-50.00%
31 Mar, 22433.33%
31 Dec, 213-
30 Sep, 21350.00%
30 Jun, 212100.00%
31 Mar, 211-
31 Dec, 201-
30 Sep, 201-
30 Jun, 201-
31 Mar, 201-
31 Dec, 19--

1 institutional shareholders have reduced their position in CNSP stock as of 30 Sep 22 compared to 2 in the previous quarter (a -50.00% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
30 Sep, 2216-5.88%1,282,3897.15%96.10%1.19%7-22.22%1-50.00%
30 Jun, 22176.25%1,196,819-30.11%89.69%0.51%9-10.00%2-50.00%
31 Mar, 2216-11.11%1,712,43049.80%132.38%0.78%1025.00%433.33%
31 Dec, 21185.88%1,143,17920.64%130.14%1.21%8-11.11%3-
30 Sep, 2117-5.56%947,605-28.57%103.59%0.42%9-350.00%
30 Jun, 21185.88%1,326,6644.15%156.49%0.65%9-30.77%2100.00%
31 Mar, 211770.00%1,273,79083.12%154.93%0.98%13225.00%1-
31 Dec, 201042.86%695,601567.42%125.57%34.90%433.33%1-
30 Sep, 20716.67%104,22311.52%18.97%6.53%3200.00%1-
30 Jun, 206-33.33%93,458-9.61%17.04%4.79%1-83.33%1-
31 Mar, 20950.00%103,39415.11%18.86%5.90%6-1-
31 Dec, 196-89,825-17.88%-6---

CNS Pharmaceuticals Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Feb 06, 2024Gumulka Jerzydirector-P-PurchaseBuy33,333$0.30$10.00K43,006

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Feb 06, 2024Gumulka Jerzydirector-P-PurchaseBuy33,333$0.30$10.00K43,006

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 10, 2024Mahery Amydirector-A-AwardBuy17,500--47,420
Apr 10, 2024Mahery Amydirector-A-AwardBuy17,500$0.26$4.53K29,920
Apr 10, 2024Keyes Jeffry R.director-A-AwardBuy17,500--80,428
Apr 10, 2024Keyes Jeffry R.director-A-AwardBuy17,500$0.26$4.53K62,928
Apr 10, 2024Gumulka Jerzydirector-A-AwardBuy17,500--147,594
Apr 10, 2024Gumulka Jerzydirector-A-AwardBuy17,500$0.26$4.53K129,594
Apr 10, 2024Evans Carl Anthonydirector-A-AwardBuy17,500--147,094
Apr 10, 2024Evans Carl Anthonydirector-A-AwardBuy17,500$0.26$4.53K129,594
Apr 10, 2024Downs Christopherofficer Chief Financial OfficerA-AwardBuy40,000--241
Apr 10, 2024Downs Christopherofficer Chief Financial OfficerA-AwardBuy40,000$0.26$10.34K201
Apr 10, 2024Cockroft Bettina M.director-A-AwardBuy17,500--53,074
Apr 10, 2024Cockroft Bettina M.director-A-AwardBuy17,500$0.26$4.53K35,574
Apr 10, 2024Climaco John Mdirector, officer Chief Executive OfficerA-AwardBuy83,000--559,533
Apr 10, 2024Climaco John Mdirector, officer Chief Executive OfficerA-AwardBuy83,000$0.26$21.46K476,533
Apr 10, 2024Charles Faith L.director-A-AwardBuy17,500--64,815
Apr 10, 2024Charles Faith L.director-A-AwardBuy17,500$0.26$4.53K47,315
Feb 06, 2024Mahery Amydirector-A-AwardBuy12,420$0.25$3.14K12,420
Feb 06, 2024Gumulka Jerzydirector-A-AwardBuy33,333$0.30$10.00K112,094
Feb 06, 2024Gumulka Jerzydirector-A-AwardBuy33,333$0.30$10.00K78,761
Feb 06, 2024Gumulka Jerzydirector-P-PurchaseBuy33,333$0.30$10.00K43,006

The last insider buy of CNSP was made by Gumulka Jerzy on Feb 06 2024, buying 33,333 shares at $0.30 per share (worth $10.00K).

CNS Pharmaceuticals Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 20232--
Q2 202382400.00%
Q1 202321315.38%
Q4 20221425.00%
Q2 20222--
Q1 20224--
Q4 20213--
Q3 20214--
Q1 20212--
Q3 20201--
Q2 202041400.00%
Q4 20191616.67%

2 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by CNS Pharmaceuticals's insiders, as of Q3 2023.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 20232--
Q2 20234--
Q1 2023-13-
Q4 2022-4-
Q2 2022---
Q1 2022---
Q4 20212--
Q3 2021---
Q1 2021---
Q3 20201--
Q2 2020---
Q4 2019---

As of Q3 2023, Insider owners conducted 2 open market buy trades and 0 open market sell trades of CNS Pharmaceuticals's stocks.

CNS Pharmaceuticals Peer Ownership


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
CWBRCohBar, Inc.
VECTVectivBio Holding AG
ELEVElevation Oncology, Inc.
IMMXImmix Biopharma, Inc.
OCEAOcean Biomedical, Inc.
EFTReFFECTOR Therapeutics, Inc.
ENVBEnveric Biosciences, Inc.
AVROAVROBIO, Inc.
HEPAHepion Pharmaceuticals, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.

CNSP Ownership FAQ


CNS Pharmaceuticals is owned by institutional shareholders (96.10%), insiders (8.55%), and public (-4.66%). The largest institutional shareholder of CNS Pharmaceuticals is ARMISTICE CAPITAL, LLC (9.11% of total shares) and the top mutual fund owner is VANGUARD INDEX FUNDS (0.00% of total shares).

CNS Pharmaceuticals's major institutional shareholders are ARMISTICE CAPITAL, LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, TOWER RESEARCH CAPITAL LLC (TRC), and VIRTU FINANCIAL LLC. The top five shareholders own together 13.72% of the company's share outstanding.

As of Sep 2022, there are 16 institutional shareholders of CNS Pharmaceuticals.

ARMISTICE CAPITAL, LLC owns 124K shares of CNS Pharmaceuticals, representing 9.11% of the company's total shares outstanding, valued at $124M (as of Mar 2023).

As of Mar 2023, RENAISSANCE TECHNOLOGIES LLC holds 26.8K shares of CNS Pharmaceuticals (CNSP), compromising 1.97% of the company, valued at $27K.

CITADEL ADVISORS LLC is the third largest holder of CNS Pharmaceuticals. The company owns 13.2K of the company's shares outstanding (worth $13.2M).